Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome

Guo, Jia; Song, Wenping; Boulanger, Joseph; Xu, Ethan Y.; Wang, Fang; Zhang, Yanqin; He, Qun; Wang, Suxia; Yang, Li; Pryce, Cynthia; Phillips, Lucy; MacKenna, Deidre A.; Leberer, Ekkehard; Ibraghimov‐Beskrovnaya, Oxana; Ding, Jie; Liu, Shiguang

doi:10.1089/hum.2018.205

Cited by 41 publications

(47 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More specifically, miR-21-5p expression was positively correlated with the serum creatinine concentration, whilst it was negatively correlated with GFR [ 141 ]. The expression pattern of miR-21-5p has also been examined in the kidneys of Alport syndrome patients [ 142 ]. The miR expression was significantly increased in kidney samples from Alport syndrome patients compared to controls and miR-21-5p levels positively correlated with serum BUN, serum creatinine, proteinuria, and overall severity of kidney pathology.…”

Section: Mirs In Kidney Diseasementioning

confidence: 99%

“…MiR-21-5p was also shown to be localized to damaged tubular epithelial cells and glomeruli. Furthermore, human kidney samples of patients with Alport syndrome showed abnormal expression of genes involved in fibrosis, mitochondrial function, inflammation, and kidney injury [ 142 ]. Worth mentioning are the clinical trials focusing on miR-21-5p in Alport syndrome.…”

Section: Mirs In Kidney Diseasementioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application

Peters

Floege

Biessen

et al. 2020

IJMS

View full text Add to dashboard Cite

There are still major challenges regarding the early diagnosis and treatment of chronic kidney disease (CKD), which is in part due to the fact that its pathophysiology is very complex and not clarified in detail. The diagnosis of CKD commonly is made after kidney damage has occurred. This highlights the need for better mechanistic insight into CKD as well as improved clinical tools for both diagnosis and treatment. In the last decade, many studies have focused on microRNAs (miRs) as novel diagnostic tools or clinical targets. MiRs are small non-coding RNA molecules that are involved in post-transcriptional gene regulation and many have been studied in CKD. A wide array of pre-clinical and clinical studies have highlighted the potential role for miRs in the pathogenesis of hypertensive nephropathy, diabetic nephropathy, glomerulonephritis, kidney tubulointerstitial fibrosis, and some of the associated cardiovascular complications. In this review, we will provide an overview of the miRs studied in CKD, especially highlighting miR-103a-3p, miR-192-5p, the miR-29 family and miR-21-5p as these have the greatest potential to result in novel therapeutic and diagnostic strategies.

show abstract

Section: Mirs In Kidney Diseasementioning

confidence: 99%

Section: Mirs In Kidney Diseasementioning

confidence: 99%

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application

Peters

Floege

Biessen

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…However, whether RG-012 can slow ADPKD progression remains to be seen. 73,74 Despite this early success, unanswered questions lie ahead. An obvious question is whether there will be off-target effects of these drugs.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Polycystic Kidney Disease

Sun

2020

Kidney Medicine

View full text Add to dashboard Cite

Important advances have been made regarding the diagnosis and management of polycystic kidney diseases. Care of patients with polycystic kidney diseases has moved beyond supportive care for complications and chronic kidney disease to new potentially disease-modifying therapies. Recently, the role of noncoding RNAs, in particular microRNAs, has been described in polycystic kidney diseases. microRNAs are involved in the regulation of gene expression, in which PKD1, PKD2, and other genes that contribute to the pathogenesis of polycystic kidney diseases are considerable participants. Seminal studies have highlighted the potential importance of microRNAs as new therapeutic targets and innovative diagnostic and/or prognostic biomarkers. Furthermore, an anti-miR-17 drug has advanced through preclinical autosomal dominant polycystic disease studies, and an anti-miR-21 drug has already cleared a phase 1 clinical trial. Most probably, new drugs in the microRNA research field will be yielded as a result of ongoing and planned therapeutic trials. To provide a foundation for understanding microRNA functions as a disease-modifying therapeutic drug in novel targeted therapies, in this narrative review we present an overview of the current knowledge of microRNAs in the pathogenesis of polycystic kidney diseases.

show abstract

“…The role of miRNAs in various cellular processes has been established, including cell division and death, cellular development, proliferation, replicative senescence, intracellular signaling and aging [16,23,[49][50][51][52][53]. It is now clear that dysregulated expression of miRNAs can exert profound effects on cells function and, as a result, leads to various pathological and occasionally malignant outcomes [54][55][56][57]. The involvement of miRNAs was showed in more than 70 different diseases such as cancer, viral infection, gastrointestinal malignancies, diabetes, immune-related diseases, and neurodegenerative disorders [51,53,[58][59][60][61][62][63][64].…”

Section: Clinical Applications Of Mirnasmentioning

confidence: 99%

Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions

Sarshar

Scribano

Ambrosi

et al. 2020

Cancers

View full text Add to dashboard Cite

Over the past decade, short non-coding microRNAs (miRNAs), including circulating and fecal miRNAs have emerged as important modulators of various cellular processes by regulating the expression of target genes. Recent studies revealed the role of miRNAs as powerful biomarkers in disease diagnosis and for the development of innovative therapeutic applications in several human conditions, including intestinal diseases. In this review, we explored the literature and summarized the role of identified dysregulated fecal miRNAs in intestinal diseases, with particular focus on colorectal cancer (CRC) and celiac disease (CD). The aim of this review is to highlight one fascinating aspect of fecal miRNA function related to gut microbiota shaping and bacterial metabolism influencing. The role of miRNAs as “messenger” molecules for inter kingdom communications will be analyzed to highlight their role in the complex host-bacteria interactions. Moreover, whether fecal miRNAs could open up new perspectives to develop novel suitable biomarkers for disease detection and innovative therapeutic approaches to restore microbiota balance will be discussed.

show abstract

Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome

Cited by 41 publications

References 58 publications

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application

MicroRNAs and Polycystic Kidney Disease

Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions

Contact Info

Product

Resources

About